China Intravenous Iron Drugs Market Size & Outlook
China intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
China intravenous iron drugs market highlights
- The China intravenous iron drugs market generated a revenue of USD 31.6 million in 2023 and is expected to reach USD 151.2 million by 2030.
- The China market is expected to grow at a CAGR of 25.1% from 2024 to 2030.
- In terms of segment, iron sucrose was the largest revenue generating product in 2023.
- Ferric Carboxymaltose is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2023 | USD 31.6 million |
| Market revenue in 2030 | USD 151.2 million |
| Growth rate | 25.1% (CAGR from 2023 to 2030) |
| Largest segment | Iron sucrose |
| Fastest growing segment | Ferric Carboxymaltose |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, China accounted for 1.0% of the global intravenous iron drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 151.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Iron sucrose was the largest segment with a revenue share of 22.47% in 2023. Horizon Databook has segmented the China intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in prevalence of cancer in the country is one of the major factors anticipated to boost its market in the near future. According to IARC, approximately 4,568,754 individuals were diagnosed with cancer in the country. This included 416,371 breast cancer cases, 555,477 color ectum cancer cases, 410,038 liver cancer cases, 815,563 lung cancer cases, and 1,892,797 other cancers.
The same source mentioned that by 2025, the prevalence of cancer is expected to increase to 9,294,006 cases in the country. In addition, 3,002,899 deaths were recorded due to cancer in China. Furthermore, due to the existence of numerous competitors worldwide, the market for IV iron drugs remains highly competitive.
For instance, in November 2022, CSL Vifor & Fresenius Kabi revealed that China's National Medical Products Administration (NMPA) granted approval for Ferinject, a solution for IV iron treatment for the management of iron deficiency in adults for whom oral iron preparations to deliver iron quickly.
Reasons to subscribe to China intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into China intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China intravenous iron drugs market size, by product, 2018-2030 (US$M)
China Intravenous Iron Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
